相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment
Allison M. Bock et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2022)
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma
Preetesh Jain et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Frederick L. Locke et al.
BLOOD (2021)
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
Martin Hutchings et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Martin Hutchings et al.
LANCET (2021)
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) versus salvage chemotherapy in refractory large B-cell lymphoma
Sattva S. Neelapu et al.
Blood Advances (2021)
Sinusoidal obstruction syndrome: a warning about autologous stem cell transplantation preceded by regimens containing oxaliplatin
Pierre-Edouard Debureaux et al.
BONE MARROW TRANSPLANTATION (2020)
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
George W. Wright et al.
CANCER CELL (2020)
Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome
Selim Corbacioglu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Constantine S. Tam et al.
BLOOD (2019)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib
Elizabeth M. Kander et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
Craig S. Sauter et al.
BLOOD (2018)
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study
E. Van den Neste et al.
BONE MARROW TRANSPLANTATION (2017)
Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed/refractory lymphoma patients
F. Tixier et al.
HEMATOLOGICAL ONCOLOGY (2017)
CANADIAN CANCER TRIALS GROUP (CCTG) LY.17: A RANDOMIZED PHASE II STUDY EVALUATING NOVEL SALVAGE THERAPY PRE-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RR-DLBCL) - OUTCOME OF IBRUTINIB + R-GDP
J. Kuruvilla et al.
HEMATOLOGICAL ONCOLOGY (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
Targeting B-cell non Hodgkin lymphoma: New and old tricks
Antonio Giovanni Solimandoa et al.
LEUKEMIA RESEARCH (2016)
Diffuse large B-cell lymphoma: R-CHOP failure-what to do?
Bertrand Coiffier et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson et al.
NATURE MEDICINE (2015)
Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
Muhammad Ary Zucha et al.
Oncotarget (2015)
Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12
Michael Crump et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
Anas Younes et al.
LANCET ONCOLOGY (2014)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study
Catherine Thieblemont et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Julie Lignon et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2010)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma
D Machover et al.
ANNALS OF ONCOLOGY (2001)
分享论文
